Article
Apolipoprotein D is associated with long-term outcome in patients with schizophrenia.
The pharmacogenomics journal - 1 Jan 2000
Hansen T, Hemmingsen R P, Wang A G, Olsen L, Timm S, Søeby K, Jakobsen K D, Fenger M, Parnas J, Rasmussen H B, Werge T
Abstract excerpt
Accumulating evidence implicates deficiencies in apolipoprotein D (ApoD) function and arachidonic acid signaling in schizophrenic disorders. We addressed two hypotheses in relation to ApoD: first, polymorphisms in the ApoD gene confer susceptibility to or are markers of disease, and, second, genetic variation in the ApoD is associated with long-term clinical outcome to antipsychotic treatment. We genotyped two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.